Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
Completed
VA Office of Research and Development
Phase 2
2006-07-01
Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis
(IPF) patients function better. This study will test whether sildenafil improves the ability
to exercise in patients with pulmonary fibrosis of unknown cause.
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
Completed
Bayer
Phase 1
2007-03-01
The purpose of this study is to assess the safety and tolerability of sorafenib in patients
with PAH already on existing therapy with a prostacyclin [epoprostenol (Flolan)],
treprostinil (Remodulin), or iloprost alone, or with or without sildenafil (Viagra/Revatio).
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
Completed
University of Chicago
Phase 1
2007-03-01
The purpose of this study is to assess the safety and tolerability of sorafenib in patients
with PAH already on existing therapy with a prostacyclin [epoprostenol (Flolan)],
treprostinil (Remodulin), or iloprost alone, or with or without sildenafil (Viagra/Revatio).
In this study, the investigators will evaluate the effect of sildenafil on exercise tolerance
in patients with a single cardiac ventricle who have undergone the Fontan operation. The
investigators will also evaluate echocardiographic measures of ventricular function and
measure quality of life changes using two validated quality of life measures. The hypothesis
is that sildenafil will result in increased exercise tolerance in patients who have had the
Fontan operation as compared to placebo.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.